Evidence map›Paper›PMID 41770946›Full record

ReviewExpert opinion on therapeutic targets2026

Lipopolysaccharide-targeting treatments for multidrug-resistant

Meggie Wang, Natalia V Kirienko

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on therapeutic targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. R pyocin sensitivity ofJournal of medical microbiology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Meggie WangDepartment of BioSciences, Rice University, Houston, TX, USA.
Natalia V KirienkoDepartment of BioSciences, Rice University, Houston, TX, USA.

Funding

Molecular Basis of Infectious Diseases Training GrantT32AI055449 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2005 to 2025
$2.6M
Targeting Multidrug-Resistant Pseudomonas aeruginosa with R PyocinsR21AI193182 · NIAID · RICE UNIVERSITY · PI KIRIENKO, NATASHA · 2025 to 2025
$440k
Molecular mechanisms for clinical dominance of P. aeruginosa ST111 isolatesR21AI176089 · NIAID · RICE UNIVERSITY · PI KIRIENKO, NATASHA · 2024 to 2025
$414k
NIAID NIH HHS R21 AI176089NIAID NIH HHS R21 AI193182NIAID NIH HHS T32 AI055449
6 · The paper itself

Abstract

introductionAREAS COVERED: This review aims to describe the current variety of LPS-targeting anti-Pseudomonals, including antimicrobials, bacteriophages, and pyocins, and how research is working to combat the rise of multi-drug resistant (MDR) EXPERT OPINION: Pyocins, bacteriocins produced by

Indexed as

Anti-Bacterial AgentsPseudomonas InfectionsAnimalsCystic FibrosisDrug DevelopmentDrug Resistance, Multiple, BacterialHumansLipopolysaccharidesPseudomonas aeruginosaPyocinsSpecies SpecificityAnti-Bacterial AgentsLipopolysaccharidesPyocinsAntimicrobialslipopolysaccharidemulti-drug resistancephage therapyPseudomonas aeruginosapyocins

Identifiers

PMID41770946
PMCPMC13076032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.